148 related articles for article (PubMed ID: 24534286)
1. Cluster analysis of cardiovascular and metabolic risk factors in women of reproductive age.
Tzeng CR; Chang YC; Chang YC; Wang CW; Chen CH; Hsu MI
Fertil Steril; 2014 May; 101(5):1404-10. PubMed ID: 24534286
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?
Daan NM; Louwers YV; Koster MP; Eijkemans MJ; de Rijke YB; Lentjes EW; Fauser BC; Laven JS
Fertil Steril; 2014 Nov; 102(5):1444-1451.e3. PubMed ID: 25239303
[TBL] [Abstract][Full Text] [Related]
3. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
[TBL] [Abstract][Full Text] [Related]
4. Seasonal effects on vitamin D status influence outcomes of lifestyle intervention in overweight and obese women with polycystic ovary syndrome.
Thomson RL; Spedding S; Brinkworth GD; Noakes M; Buckley JD
Fertil Steril; 2013 May; 99(6):1779-85. PubMed ID: 23357457
[TBL] [Abstract][Full Text] [Related]
5. Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome.
Panidis D; Rousso D; Koliakos G; Kourtis A; Katsikis I; Farmakiotis D; Votsi E; Diamanti-Kandarakis E
Fertil Steril; 2006 Jun; 85(6):1778-83. PubMed ID: 16650418
[TBL] [Abstract][Full Text] [Related]
6. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
Verit FF
Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
[TBL] [Abstract][Full Text] [Related]
7. Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes.
Wiltgen D; Spritzer PM
Fertil Steril; 2010 Nov; 94(6):2493-6. PubMed ID: 20338557
[TBL] [Abstract][Full Text] [Related]
8. Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome.
Sung YA; Oh JY; Chung H; Lee H
Fertil Steril; 2014 Mar; 101(3):840-5. PubMed ID: 24424368
[TBL] [Abstract][Full Text] [Related]
9. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
Graff SK; Mário FM; Alves BC; Spritzer PM
Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome.
Soares EM; Azevedo GD; Gadelha RG; Lemos TM; Maranhão TM
Fertil Steril; 2008 Mar; 89(3):649-55. PubMed ID: 17543961
[TBL] [Abstract][Full Text] [Related]
12. Ovarian hyperandrogenism in adolescents and young women with type I diabetes is primarily related to birth weight and body mass index.
Bizzarri C; Benevento D; Ravà L; Patera IP; Schiaffini R; Ciampalini P; Giannone G; Cappa M
Fertil Steril; 2011 Dec; 96(6):1497-1502.e1. PubMed ID: 21982726
[TBL] [Abstract][Full Text] [Related]
13. Impact of adrenal versus ovarian androgen ratio on signs and symptoms of polycystic ovarian syndrome.
Köşüş N; Köşüş A; Kamalak Z; Hızlı D; Turhan NÖ
Gynecol Endocrinol; 2012 Aug; 28(8):611-4. PubMed ID: 22296561
[TBL] [Abstract][Full Text] [Related]
14. Long-term consequences of polycystic ovary syndrome on cardiovascular risk.
Rizzo M; Berneis K; Spinas G; Rini GB; Carmina E
Fertil Steril; 2009 Apr; 91(4 Suppl):1563-7. PubMed ID: 18976752
[TBL] [Abstract][Full Text] [Related]
15. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
16. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
[TBL] [Abstract][Full Text] [Related]
17. Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome.
Gateva AT; Kamenov ZA
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):161-6. PubMed ID: 22727921
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women.
Liou TH; Yang JH; Hsieh CH; Lee CY; Hsu CS; Hsu MI
Fertil Steril; 2009 Dec; 92(6):1960-5. PubMed ID: 18980763
[TBL] [Abstract][Full Text] [Related]
20. Is hepcidin a new cardiovascular risk marker in polycystic ovary syndrome?
Gözdemir E; Kaygusuz I; Kafalı H
Gynecol Obstet Invest; 2013; 75(3):196-202. PubMed ID: 23548757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
